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Objectives: The “Pneumonia Zero” project is a nationwide multimodal 
intervention based on the simultaneous implementation of a compre-
hensive evidence-based bundle measures to prevent ventilator-asso-
ciated pneumonia in critically ill patients admitted to the ICU.
Design: Prospective, interventional, and multicenter study.
Setting: A total of 181 ICUs throughout Spain.
Patients: All patients admitted for more than 24 hours to the par-
ticipating ICUs between April 1, 2011, and December 31, 2012.
Intervention: Ten ventilator-associated pneumonia prevention 
measures were implemented (seven were mandatory and three 
highly recommended). The database of the National ICU-Acquired 
Infections Surveillance Study (Estudio Nacional de Vigilancia 
de Infecciones Nosocomiales [ENVIN]) was used for data col-
lection. Ventilator-associated pneumonia rate was expressed as 
incidence density per 1,000 ventilator days. Ventilator-associated 
pneumonia rates from the incorporation of the ICUs to the project, 
every 3 months, were compared with data of the ENVIN registry 
(April–June 2010) as the baseline period. Ventilator-associated 
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pneumonia rates were adjusted by characteristics of the hospital, 
including size, type (public or private), and teaching (postgradu-
ate) or university-affiliated (undergraduate) status.
Measurements and Main Results: The 181 participating ICUs 
accounted for 75% of all ICUs in Spain. In a total of 171,237 
ICU admissions, an artificial airway was present on 505,802 days 
(50.0% of days of stay in the ICU). A total of 3,474 ventilator-asso-
ciated pneumonia episodes were diagnosed in 3,186 patients. 
The adjusted ventilator-associated pneumonia incidence density 
rate decreased from 9.83 (95% CI, 8.42–11.48) per 1,000 ven-
tilator days in the baseline period to 4.34 (95% CI, 3.22–5.84) 
after 19–21 months of participation.
Conclusions: Implementation of the bundle measures included in 
the “Pneumonia Zero” project resulted in a significant reduction 
of more than 50% of the incidence of ventilator-associated pneu-
monia in Spanish ICUs. This reduction was sustained 21 months 
after implementation. (Crit Care Med 2018; 46:181–188)
Key Words: guideline adherence; intensive care units; prevention 
& control; ventilator-associated pneumonia
The prevalence rates of ventilator-associated pneumonia (VAP) is a common indicator for safety and quality of care in critically ill patients admitted to the ICU (1, 2). 
Morbidity and mortality attributed to VAP have been exten-
sively documented in the literature (3–6). Specific programs for 
the prevention of this infection have been included in national 
campaigns promoted in the United States with the objective to 
reduce mortality (The 100,000 lives campaign) (7, 8).
In Spain, healthcare-associated infection rates in critical care are 
collected in the database of the National ICU-Acquired Infection 
Surveillance Study (ENVIN-HELICS registry) in which clinical 
data of patients admitted to Spanish ICUs from April 1 to June 30 
each year are captured. From 2000 to 2008, Spanish national VAP 
rates have remained stable at around 15 episodes per 1,000 ventila-
tor days (9, 10). In recent years, benefits of the implementation of 
sets of different preventive measures or bundles to reduce health-
care-associated infections, such as catheter-related bloodstream 
infection (CRBSI) (11, 12) or VAP (13–22), have been reported. 
In Spain, a multifaceted intervention to prevent CRBSI was imple-
mented during 2009–2010, the so-called “Bacteremia Zero” proj-
ect, resulted in a 50% risk reduction of bloodstream infections 
(23). Based on the organizational structure of “Bacteremia Zero,” 
a new nationwide project, called “Pneumonia Zero,” was designed 
to implement a bundle of VAP-specific preventive measures (23). It 
was hypothesized that implementation of the intervention would 
result in a significant reduction of VAP rates. The main objective of 
this study was to assess the impact of the “Pneumonia Zero” proj-
ect in reducing the rates of VAP in Spanish ICUs.
MATERIALS AND METHODS
Design and Setting
We designed a prospective, interventional, and multicenter 
study. Adult ICUs from the 17 HealthCare Regions of the Span-
ish National HealthCare System or from the private sector were 
invited to participate in the “Pneumonia Zero” project. The study 
period lasted 21 months, from April 1, 2011 to December 31, 
2012. The annual Spanish registry of healthcare-associated infec-
tions in critically ill patients (ENVIN-HELICS registry) was used 
for data collection. The first 3 months matched the annual data 
collection time frame of the annual Spanish registry of health-
care-associated infections in critically ill patients (April 1, 2010, 
to June 30, 2010) and were considered the baseline period (9).
Participation in the study was voluntary and required pro-
vision of basic data (number of VAP episodes and number of 
days on mechanical ventilation) and adherence to the bundle 
recommendations for at least 6 months during the 21 months 
of the study period.
Structure and Organization
The Spanish Ministry of Health, Social Policy and Equality 
provided national supervision and program coordination 
in collaboration with the Regional Health Care Authorities, 
which were in charge of coordination at regional level and 
provided the necessary resources for implementation. The 
Spanish Society of Intensive and Critical Care Medicine and 
Coronary Units (SEMICYUC) and the Spanish Society of 
Intensive Nursing and Coronary Units were in charge of tech-
nical coordination of the project. An intensivist and a critical 
care nurse in each ICU were appointed to as local leaders.
A detailed description of the VAP prevention bundle and 
tools developed for its implementation and control of adher-
ence has been published previously (24). The bundle includes 
seven basic mandatory measures and three highly recom-
mended measures all of which with proven efficacy in the pre-
vention of VAP (24) (Table 1). The study protocol was approved 
by the Clinical Research Ethics Committee of Hospital del Mar, 
Barcelona (Spain). Also, the institutional review boards waived 
the need for informed consent.
Patients
All patients admitted for more than 24 hours to the participat-
ing ICUs between April 1, 2011, and December 31, 2012, were 
included in the study. Patients who developed one or more epi-
sodes of VAP during their stay in the ICU were compared with 
those who developed VAP during the baseline period (April–
June 2010). Criteria for the diagnosis of VAP in the ENVIN-
HELICS registry (9) are in accordance with the European 
Centre for Disease Prevention and Control (25) and included 
the following: 1) two or more sequential chest x-rays or CT 
scans with a suggestive image of pneumonia for patients with 
underlying cardiac or pulmonary disease, or one definitive 
chest x-ray or CT scan in patients without underlying cardiac 
or pulmonary disease; 2) fever greater than 38°C and/or leu-
kocytosis greater than or equal to 12,000 WBC/mm3 or leu-
kopenia less than or equal to 4,000 WBC/mm3; and 3) at least 
one of the following: a) new onset purulent sputum or change 
in the characteristics of sputum; b) cough, dyspnea, or tachy-
cardia; c) suggestive of auscultation (rales or bronchial breath 
sounds), ronchi, wheezing; or d) worsening gas exchange (e.g., 
oxygen desaturation or increased oxygen requirements or 
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increased ventilation demand). For the diagnosis of a second 
pneumonia at least two of the following was required: 1) new 
suggestive signs and symptoms; 2) radiologic evidence or other 
diagnostic tests at least after 2 days of clinical resolution; and 
3) isolation of a microorganism different from the causative 
pathogen of the first episode or an interval of 2 weeks between 
two samples in case of the same microorganism. VAP episodes 
were additionally stratified according to the microbiological 
sampling diagnostic method employed (9). Patients were fol-
lowed up to 48 hours after discharge from the ICU.
Workshops were held in all regions in order to guarantee a 
homogeneous use of the definition of VAP. Prior to the beginning 
of the project, from April to June 2010, an audit of the ENVIN-
HELICS registry (23) had established the adequacy of the col-
lected diagnoses of VAP. Also, annual national meetings were 
held to provide updates, follow-up, description of barriers and 
to promote improvement strategies at local and regional levels.
Data Collection
The “ENVIN-HELICS” database (restricted access via password) 
was adapted to facilitate specific data collection for the “Pneu-
monia Zero” project (http://hws.vhebron.net/Neumonia-zero/). 
Monthly unit data were entered by local coordinators, including 
the number of ICU admissions, total patient days in the ICU and 
on mechanical ventilation. The device use ratio was calculated as 
days of mechanical ventilation divided by days of ICU stay.
For patients developing one or more episodes of VAP, addi-
tional data recorded were as follows: demographics (age, sex), 
severity of illness on ICU admission using the Acute Physiology 
and Chronic Health Evaluation II score (26), comorbidities, 
risk factors for ICU-acquired infection, length of ICU stay, 
days of ICU stay before diagnosis of VAP was established, and 
mortality. VAP rates were compared between public and pri-
vate hospitals, university-affiliated (undergraduate) and teach-
ing (postgraduate) hospitals, and small (< 200 beds), medium 
(200–500 beds), and large (> 500 beds) hospitals. The degree 
of adherence to recommendations included in the bundle was 
recorded. Adherence was assessed using a survey. Questions in 
the survey were designed to capture daily activities reflecting 
compliance with components of the VAP prevention bundle. 
Questions asked were 1) whether an internal audit about the 
quality of adherence to four recommendations (aspiration of 
tracheal secretions, oral hygiene with chlorhexidine, control 
and maintenance of cuff pressure, and control of semirecum-
bent positioning) had been performed and 2) implementation 
or use the 10 recommendations in the ICU. The survey was 
sent by e-mail to the local physician intensivist leader of the 
project at each of the 181 participating ICUs, 109 of which 
responded. Adherence was expressed as a percentage of the 
number of responses received and the total number of partici-
pating units. We hypothesized that adherence varies between a 
maximum value, if calculated as the percentage of adherence 
expressed in responses, and a minimum value, if calculated as 
the percentage of adherence expressed in responses over total 
of surveys sent. The length of follow-up (duration of participa-
tion) for each participating ICU was also registered.
An online training course for healthcare professionals 
involved in the project was available on ENVIN-HELICS plat-
form. The course included clinical aspects of VAP prevention 
and basic concepts of patient safety to learn from errors and pro-
mote teamwork. Furthermore, the number of staff completing 
the 6-hour online training course was recorded. Every ICU had 
online access to its own data and descriptive analysis. At regional 
and national levels, aggregated information was available.
TABLE 1.  Individual Components of the Ventilator-Associated Pneumonia Prevention 
Bundle
Seven Basic Mandatory Measures Three Highly Recommended Measures
1. Education and training in appropriate airway management.a 1. Selective decontamination of the digestive tract or selective 
oropharyngeal decontamination.
2. Strict hand hygiene with alcohol solutions before airway 
 management.
2. Continuous aspiration of subglottic secretions.
3. Control and maintenance of cuff pressure. 3. Short course (2-3 doses) of systemic antibiotics during intu-
bation of patients with previous decreased consciousness.
4. Oral hygiene with chlorhexidine.  
5. Semirecumbent positioning. Avoidance of 0° supine positioning 
if possible.  
6. Promoting procedures and protocols that safely avoid or 
reduce duration of mechanical ventilation.b  
7. Avoidance of elective changes of ventilator circuits, humidifiers, 
and endotracheal tubes.  
a Two educational modules about ventilator-associated pneumonia prevention and patient safety with their corresponding examinations are freely accessible on-
line (http://hws.vhebron.net/envin-helics/) and continuously monitored for ICUs successfully completing the tests. Coordinators in each unit have access to this 
registry and report to the regional coordinators.
b Protocols for noninvasive mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease, for weaning or sedation promoting lower 
infusion doses or its daily interruption should be available.
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Exposure and Outcomes
Exposure was defined as the implementation period of the 
study intervention (April 1, 2011, to December 31, 2012), 
rendering quarterly VAP rates for comparison with the base-
line period rate obtained in the April to June 2010 ENVIN-
HELICS study period (http://hws.vhebron.net/envin-helics/). 
The primary outcome was the quarterly rate of VAP. Secondary 
outcomes were the rates of VAP according to hospital features 
(type, teaching status, and size).
Statistical Analysis
The characteristics of patients with VAP diagnosed during the 
intervention period were compared with those of the baseline 
period. Quantitative variables were expressed as mean and sd 
or median and interquartile range (IQR) (25–75th percentile) 
as appropriate. Categorical variables are expressed as frequen-
cies and percentages. Continuous data were compared using 
Student’s t test or Mann-Whitney U test, and categorical data 
with the chi-square test or the Fisher exact test according to 
distribution and size of the variables.
The number of VAP episodes, days of mechanical ventilation, 
and incidence rates were expressed as median and IQR. Median 
monthly data were aggregated in quarters. The implementation 
period for each ICU was analyzed by quarters of participation 
starting on the date of inclusion in the study. The quarterly infec-
tion rate was calculated as the number of infections per 1,000 
mechanical ventilation days for each 3-month period. To explore 
the exposure-outcome relationship, we used generalized linear 
mixed regression models with a Poisson distribution (27) to calcu-
late the incidence rates, incidence rate ratio, and 95% CI, consid-
ering the ICU unit as random and the other factors as fixed effects. 
In the final regression analysis, period estimates were adjusted by 
hospital type, teaching status, and size. All tests of significance were 
two sided and set at p value of less than 0.05. We used R version 
3.1.2 language for statistical analysis (R Foundation for Statistical 
Computing, Vienna, Austria, 2014; http://www.R-project.org).
RESULTS
A total of 181 ICUs participated in the “Pneumonia Zero” 
project, with a total of 171,237 admissions, 1,011,782 days of 
ICU stay, and a rate of artificial airway use of 50.5% (505,802 
d of mechanical ventilation). Participation in the project dur-
ing the whole 21-month study period occurred in 132 ICUs 
(72.9%). The duration of participation for each ICU is shown 




 Recommendations  
(n)
ICUs That 
 Responded to  
the Survey  
(n = 109) (%)
Participating ICUs in  
the “Pneumonia  
Zero” Project  
(n = 181) (%)
Internal audits    
 Aspiration tracheal secretionsa 95 87.2 52.5
 Oral hygiene with chlorhexidine 94 86.2 51.9
 Control and maintenance of cuff pressurea 105 96.3 58.0
 Control of semirecumbent positioninga 109 100 60.2
Survey questions    
 Strict hand hygiene for airway management (education) 105 96.3 58.0
 Routine change of ventilator circuit (no) 97 90.0 53.6
 Change of filters or humidifiers within 48 hr (no) 91 83.5 50.3
 Known and consensus sedation protocols available (yes) 58 53.2 32.0
 Known and consensus protocols of mechanical ventilation 
withdrawal available (yes)
50 45.9 27.6
 Known and consensus protocol of noninvasive ventilation 
available (yes)
36 33.0 19.9
 Routine use of orotracheal tubes with subglottic aspiration 
(yes)
55 50.5 30.4
 Routine use of tracheal tubes with subglottic aspiration (yes) 17 15.6 9.4
 Routine use of selective digestive decontamination (yes) 32 29.4 17.7
 Routine use of systemic antibiotics during intubation of 
patients with previous decreased consciousness (yes)
72 66.1 39.8
a For each intervention, it was requested that adherence was assessed a minimum of 10 times. An ICU had accomplished this goal if adequate implementation 
was measured on at least 10 occasions.
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in Table 1-e (Supplemental Digital Content 1, http://links.
lww.com/CCM/C886). ICUs from large hospitals (> 500 beds) 
accounted for 44.7% of the total participating units, ICUs from 
medium-size hospitals (200–500 beds) for 42.0%, and ICUs 
from small hospitals (< 200 beds) for 13.3%. Also, there were 
119 (65.7%) university-affiliated hospitals, 171 (94.5%) pub-
lic hospitals, and 157 (86.7%) were certified for postgraduate 
training. A total of 109 ICUs (60.2%) completed the adherence 
survey. The results of the survey are shown in Table 2.
During the intervention period, a total of 3,474 episodes of 
VAP were diagnosed in 3,186 patients (6.87 episodes of VAP 
per 1,000 d of mechanical ventilation). The number of partici-
pating ICUs, admitted patients, days at risk (artificial airway), 
and patients with one or more episodes of VAP at baseline and 
per quarter are shown in Table 3. The percentage of patients 
with VAP decreased from 2.4% at baseline to 1.9% during the 
intervention period (p < 0.0001). ICUs with prolonged par-
ticipation of 19–21 months achieved an even lower mean inci-
dence of VAP of 1.2% (p < 0.0001). Fewer patients suffered 
from more than one episode of VAP during the intervention 
period compared with the baseline period (7.7% vs 10.9%; 
p = 0.037).
The characteristics of the 542 patients who developed VAP 
during the baseline period were similar to those of the 3,189 
patients with VAP during the intervention period (Table 2-e, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
C886). Diagnostic sampling methods, associated systemic 
response, and etiology of VAP episodes are shown in Table 
3-e (Supplemental Digital Content 1, http://links.lww.com/
CCM/C886). During the intervention period, episodes of VAP 
occurred 2 days later than during the baseline period (median 
[IQR] 8.0 [4.0–16.0] vs 6.0 [3.0–13.0] d; p < 0.001).
The median incidence densities of VAP of those ICUs par-
ticipating in both baseline and all subsequent quarters of expo-
sure to the intervention are shown in Table 4-e (Supplemental 
Digital Content 1, http://links.lww.com/CCM/C886). The 
adjusted incidence density of VAP by hospital characteristics 
(Table 4) showed a 55.8% decrease, from a median (IQR) 
of 9.89 (8.42–11.48) to 4.34 (3.22–5.84) episodes per 1,000 
days of mechanical ventilation in ICUs with 19–21 months 
of participation in the project. Also, a lower incidence density 
rate of VAP in large hospitals (> 500 beds) was observed. A 
reduction of the incidence density rates along the intervention 
period was observed, independently of hospital size (Fig. 1).
DISCUSSION
This study shows that the implementation of a bundle of 
measures to prevent VAP (24) in Spanish ICUs was associated 
with a highly significant reduction of VAP from 9.83 episodes 
during the baseline period to 4.34 episodes per 1,000 days of 
mechanical ventilation in the last 3 months of the interven-
tion period (55.8% reduction). Furthermore, VAP occurred 2 
days later when the bundle was applied. The magnitude of the 
reduction of VAP rates was progressive throughout the dura-
tion of participation, suggesting that sustained application of 
the bundle increases its clinical impact.
To our knowledge, this is the largest study demonstrat-
ing the effectiveness of implementing a VAP-specific preven-
tion bundle at a national level. A total of 181 Spanish ICUs 
participated in the “Pneumonia Zero” project, accounting for 
approximately 75% of Spanish ICUs (28). These units had 
been involved annually since 1994 in reporting data of health-
care-related infections to a national registry (ENVIN, available 
at http://hws.vhebron.net/envin-helics/). It is the information 
available in this registry which allowed establishing baseline 
national incidence rates for VAP and to assess the effect of the 
intervention.
In recent years, a number of initiatives, mostly evidence-
based guidelines for the prevention of VAP, have been published 
(29–36). In 2002, the Institute for Healthcare Improvement 
(IHI) launched “The 100k lives campaign,” which included a 
“ventilator bundle” to prevent VAP, with measures of peptic 
ulcer prophylaxis, deep vein thrombosis prophylaxis, eleva-
tion of the head of the bed, and a sedation vacation (7, 8). The 
impact of the implementation of the IHI bundle in 61 U.S. 
hospitals was associated with a 59% reduction in VAP rates 
in hospitals with a higher than 95% adherence (13). Similar 
experiences reported by other authors in different ICU settings 
have consistently shown a reduction of VAP rates (14–22).






Postintervention1–3 4–6 7–9 10–12 13–15 16–18 19–21
Participating ICUs (n) 146 181 177 175 175 170 158 148 181
ICU admissions (n) 22,388 26,393 24,144 25,975 26,854 25,253 20,955 21,663 171,237
Patient days (n) 137,004 154,973 141,179 152,803 162,575 149,096 124,590 126,569 1,011,782
Days of intubation (n) 58.082 77.621 69.732 75.211 84.739 74.359 62.356 61.784 505.802
Patients with VAP, 
n (%)
539 (2.4) 655 (2.5) 569 (2.4) 453 (1.7) 443 (1.6) 472 (1.9) 334 (1.6) 260 (1.2) 3,186 (1.9)
Patients with > 1 
VAP, n (%)
59 (10.9) 47 (7.2) 56 (9.8) 30 (6.6) 30 (6.8) 45 (9.5) 21 (6.3) 18 (6.9) 247 (7.7)
VAP = ventilator-associated pneumonia.
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TABLE 4. Univariate and Adjusted Multivariate Analyses for Ventilator-Associated 
Pneumonia
 








Ratio (95% CI) p
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Hospital size (beds)       














 > 500 (reference)b 6.82 
(5.95–7.81)
1     




0.0476    




0.3229    
University affiliated       
 Yes (reference = 1) 6.40 
(5.70–7.19)
1    




0.3223    
Teaching hospital       
 Yes (reference = 1) 6.20 
(5.59–6.87)
1    




0.7460    
Type of hospital       
 Public (reference = 1) 6.14 
(5.56–6.78)
1    




0.3540    
a Reference for the comparison with ≤ 500 beds.
b Reference for the comparison with 200-500 beds and < 200 beds.
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Adherence to recommendations has been recognized as the 
main factor associated with reduction of VAP rates. Concanour 
et al (14) showed that VAP rates did not decrease with imple-
mentation of the ventilator bundle alone, but VAP decreased 
significantly after compliance with the ventilator bundle was 
audited daily, and weekly feedback was provided to the caregiv-
ers. Involvement of hospital managers together with continued 
education and feedback was crucial to maintain a low VAP rate 
(14). In another study, Hawe et al (37) reported a significant 
reduction of VAP rate from 19.2 to 7.5 per 1,000 ventilator days 
if a VAP prevention bundle was actively associated with a mul-
timodal program incorporating staff education, process mea-
surement, and outcome measurement, as well as feedback to 
staff and organizational change. In two surgical ICUs, Bird et 
al (18) showed a progressive decrease of the rate of VAP when 
compliance with the bundle was maintained. In our study, 
adherence to the project was documented by the completion 
of data required for calculation of rates (number of VAP epi-
sodes, days of ICU stay, and days of mechanical ventilation), 
with internal audits of the degree of compliance of four rec-
ommendations of the bundle.
The impact of the specific bundle on reduction of VAP rates 
was independent of the teaching status of the hospital and 
whether the hospital was of public or private nature. However, 
baseline and final VAP rates were higher in large hospitals with 
postgraduate and undergraduate training programs, probably 
due to differences in patient complexity and severity, as well as 
device use ratio, workload, and the increased presence of train-
ees in larger centers. It should be noted that ICU length of stay 
of patients with VAP increased significantly from baseline to the 
intervention period. A possible explanation may be the greater 
severity of VAP during the study period with an increased per-
centage of associated severe sepsis, septic shock, and increased 
cases of VAP caused by Gram-negative pathogens.
Implementation of measures for the prevention of VAP 
has been associated with training in safety, that is, our train-
ing module, which was completed during the implementa-
tion period by more than 18,000 healthcare workers, nurses 
in particular. These 18,000 healthcare workers accounted for 
approximately 83% of total workers in the participating ICUs. 
However, adherence to the use of the recommended tools 
was not measured. It should also be noted that one fourth of 
Spanish ICUs did not participate for economic reasons and 
possibly lack of motivation and leadership. Nonetheless, the 
total number of participating units is higher than that of pre-
vious national projects with the same organizational structure 
(“Bacteremia Zero” project) (23).
One of the consequences of the results presented here is that the 
reference quality indicator for VAP rate of the SEMICYUC needs 
to be adjusted. Every 5 years, the Society publishes quality refer-
ence standards which apply to Spanish ICUs, including VAP epi-
sodes per 1,000 ventilator days. For 2011, prior to the “Pneumonia 
Zero” program, the proposed rate was 12 episodes per 1,000 
days of mechanical ventilation (data available at http://www.
semicyuc.org/sites/default/files/quality_indicators_update_2011.
pdf). Based on the results of implementing “Pneumonia Zero” 
program, the authors propose to readjust the acceptable national 
standard for VAP to seven episodes per 1,000 days of mechanical 
ventilation, with adjustments to hospital size.
Limitations of our study results relate to interobserver vari-
ability, that is, risk of bias, in the diagnosis of VAP, which is 
difficult to avoid in a multicenter study with and voluntary 
participation. Performance of many training workshops aimed 
at standardizing the definition of VAP was organized to limit 
bias. In addition, results of an audit of patients included in the 
ENVIN-HELICS registry between June and April 2010 (9) con-
firmed the quality of the diagnoses of VAP. On the other hand, 
no external audit of the degree and quality of compliance with 
each of the recommendations was performed, although inter-
nal assessment of adherence of four of the recommendations 
was requested using a survey (unpublished data).
Finally, it is our unproven understanding that success of 
implementation of the VAP prevention bundle is due to the 
effect of three simultaneous factors: 1) a bundle composed of 
interventions with proven efficacy in the prevention of VAP; 
2) a pyramid shape organizational structure with participa-
tion of the Spanish Ministry of Health, the regional health 
care authorities, intensivists who are leaders in control of ICU 
infections, and other healthcare workers at a local level; and 
3) an associated certified educational program as the instru-
ment for disseminating patient safety concepts and providing 
detailed information about the implementation of well-known 
VAP prevention measures.
CONCLUSIONS
The nationwide implementation of a VAP prevention bundle 
was associated with a significant reduction of VAP rates of 
more than 50% at a national level. These findings confirm the 
hypothesis that implementation of a comprehensive evidence-
based bundle is effective in reducing VAP rates.
Figure 1. Changes of rates for ventilator-associated pneumonia for each 
time period of participation in the “Pneumonia Zero” project according to 
characteristics of the hospital (individual values of each curve are shown 
in Table 5-e, Supplemental Digital Content 1, http://links.lww.com/CCM/
C886).
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